SWTX vs. SMMT, ITCI, VTRS, GMAB, MRNA, RDY, SRPT, PCVX, QGEN, and ROIV
Should you be buying SpringWorks Therapeutics stock or one of its competitors? The main competitors of SpringWorks Therapeutics include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.
SpringWorks Therapeutics vs.
SpringWorks Therapeutics (NASDAQ:SWTX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, community ranking, profitability and analyst recommendations.
SpringWorks Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summit Therapeutics received 198 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. However, 71.43% of users gave SpringWorks Therapeutics an outperform vote while only 58.38% of users gave Summit Therapeutics an outperform vote.
Summit Therapeutics has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -203.09%. SpringWorks Therapeutics' return on equity of -48.21% beat Summit Therapeutics' return on equity.
4.6% of Summit Therapeutics shares are held by institutional investors. 7.6% of SpringWorks Therapeutics shares are held by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
SpringWorks Therapeutics presently has a consensus target price of $71.50, indicating a potential upside of 22.14%. Summit Therapeutics has a consensus target price of $33.57, indicating a potential upside of 48.77%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than SpringWorks Therapeutics.
In the previous week, SpringWorks Therapeutics had 23 more articles in the media than Summit Therapeutics. MarketBeat recorded 27 mentions for SpringWorks Therapeutics and 4 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.44 beat SpringWorks Therapeutics' score of 0.17 indicating that Summit Therapeutics is being referred to more favorably in the news media.
SpringWorks Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.88, indicating that its share price is 188% less volatile than the S&P 500.
Summary
SpringWorks Therapeutics beats Summit Therapeutics on 9 of the 17 factors compared between the two stocks.
Get SpringWorks Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SpringWorks Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SWTX) was last updated on 2/21/2025 by MarketBeat.com Staff
